Upload
gyanendra-joshi
View
855
Download
1
Embed Size (px)
Citation preview
Drugs acting on Cardiovascular system
The drugs acting on cardiovascular system are divided into four groups: Cardiotonic drugs Anti-hypertensive drugs Anti-arrhythmic drugs Anti-anginal drugs
Cardiotonic drugs
Drugs which increase the force of contraction of the heart, are called cardiotonic drugs.
Classification:
1. Cardiac glycosides 3. Anticholinergic drugs – Digoxin -Atropine– Digitoxin -Scopolamine
2. Sympathetic drug 4. Xanthines-Adrenaline -Theophylline
-Dopamine -Theobromine
-Isoprenaline
Cardiac glycosides
• Cardiac glycosides are those glycosides which have specific action to the failing heart.
• Increase the force of contraction of failing heart and lower the heart rate and thereby maintain an effective circulation.
• Classification of cardiac glycosides:Natural
A). Plant source– From leaves of foxgloves:
• Digitalis purpurea: Digoxin, Digitoxin• Digitalis lanata: Digoxin, Lanatoside-C
– From the seeds of foxgloves:• Strophanthus kombe: Cymarin, Cymarol• Strophanthus gratus: Ouabain squill
B) Animal source: Toad venom: BufotoxinSynthetic:
-Digitoxigenin
-Digoxigenin
-Gitoxigenin
Digitalis
• Digitalis is a powerful inhibitor of Na+/K+ ATPase. As a result they increase the efficiency of failing heart increasing Na+ concentration within cell membrane;which enhances Ca++ availability to the contractile apparatus and increase the contractility.
Mechanism of action: • It alters ion transport system by inhibiting membrane
bound enzyme Na+/K+ ATPase, which is associated with Na+ pump. So– It decreases active transport of Na+ out of the cell
increasing intracellular Na+ concentration; this in turn decreases Ca++ transport out of cell.
– Release of stored Ca++ from the sarcoplasmic reticulum increases.
– Permeability of Ca++ increases. The net effect is increased intracellular Ca++ ions which increases the force of contraction of the cardiac muscles.
• Pharmacological actions: Cardiac effects:
On normal heart– Direct positive inotropic action– Decrease heart rate so decrease cardiac output– Increase systolic and mean systemic arterial pressure
due to direct arteriolar contraction– Decrease central venous pressure
On failing heart– Direct action: Positive inotropic action– Indirect action: decrease sinus rate, so decrease
heart rate
• Extra-cardiac effects:1. Kidneys:
– Diuresis(due to increase renal perfusion)– oedema(due to aldosterone antagonism)
2. Eye: Xanthopsia (appearance of yellow-green tings cause visual disturbance
3. CNS: paraesthesia, toxic psychosis4. Blood vessels: vasoconstriction, venodilation5. GIT: anorexia, nausea, vomiting6. Gynaecomastia (due to prolonged use)
Indications of Digitalis:
1. Congestive heart failure due to ischemia, hypertensive or valvular heart disease.
2. Atrial fibrillation
3. Atrial flutter
4. Paroxysmal supraventricular tachycardia
5. Left ventricular failure
Contraindications – Digitalis toxicity– CVS
• Recent myocardial infarction• Heart block• Arrhythmia
– renal impairment – Hepatic failure– Electrolyte imbalance specially hypokalaemia
and hypocalcaemia
• Digitalisation: Subjection of a patient to the action of digitalis is called digitalisation.
• Cautions:– Therapeutic index of digitalis is low ( therapeutic
dose is very near to toxic dose)– The dose of digitalis should be individualized.– Danger signs of digitalis toxicity after initial dose
are: nausea, vomiting, sinus bradycardia (HR<60beats per min)
• Digitalisation is done by three ways:1. Emergency digitalisation2. Rapid digitalisation3. Slow digitalisation Total digitalisation dose (TDD):
It is the initial loading dose of digoxin.-Oral route: 0.75-1.25mg-i/v route: 0.5-1mg
• Maintenance dose: Oral route: 0.125-0.5mg i/v route: 0.25mg
Anti-hypertensive drugs
• Hypertension: Persistent rise of blood pressure above the upper limit of normal level according to the age and sex of the individual is called HYPERTENSION (HTN)
• Normal limits of blood pressure:– Systolic: 100-140 mm Hg(120±20)– Diastolic: 60-90 mm Hg (75±15)
Causes of hypertension:• Primary hypertension (90-95%):
– also called as essential hypertension– Unknown etiology or idiopathic
• Secondary hypertension(5-10%):– Renal disease– Endocrine diseases (Conn’s disease, acromegaly,
Phaeochromocytoma)– Cushing's disease– Vascular causes (renal artery stenosis, coarctation of aorta)– Drugs (sympathomimetics, NSAIDs, contraceptive pills, steroids
• Risk factors:– Age– Hereditary– Anxiety– Obesity and lack of
exercise– Alcohol consumption– Salt intake
• Special patient groups– Race– Elderly– Diabetes– Renal disease– Stroke– Pregnancy– Hormone replacement
therapy – Oral contraceptives
Management of hypertension
Non-pharmacologic approaches: Weight reduction in obese patients: reduces
about 2.5/1.5 mm Hg per kg wt. lost Restriction to salt intake: not more than 6 g NaCl Dietary considerations: legumes, fresh fruits and
vegetables, whole grains Regular exercise Restricted alcohol intake Smoking cessation to reduce cardiovascular risk
Pharmacologic approach: Classification: A. Diuretics:
– Carbonic anhydrase inhibitors : acetazolamide – Loop diuretics: Furosemide, ethacrynic acid , mercurials – Thiazide diuretics: Hydrochlorthiazide– Potassium sparing: amiloride , triamterene, spironolactone– Osmotic diuretics : mannitol
B. Sympatholytics:– Centrally acting: Methyl-dopa, Clonidine– Beta-blockers: Atenolol, Propranolol, Metoprolol– Alpha-blockers: Prazosin, Phentolamine– Adrenergic neuron blockers: Guanethidine, Reserpine
C. Direct vasodilators:• Arteriolar dilators
• Diazoxide• Hydralazine• Minoxidil• Prazosin
• Vasodilators (non-selective)• Nitroprusside• Prazosin
D. Calcium Channel blockers:– Nifedipine– Verapamil– Diltiazem
E. Angitensin converting enzyme (ACE) inhibitors:– Captopril– Enalapril– Lisinopril– Ramipril
α-Methyl dopa
• It is useful in treatment of mild to moderately severe hypertension.
• It reduces the BP chiefly by reducing peripheral vascular resistance.
• It inhibits noradrenaline synthesis: DOPA Dopamine DOPA decarboxylase α-methyl dopa methyldopamine α methyl- noradrenaline
• Remains inside the vesicles and released in the same way as noradrenaline.
Mechanism of Action
• α-Methyl dopa forms false neurotransmitter α-Methyl noradrenaline which combines with α-adrenoceptors present in the surface of the lower brain stem, inhibiting the neurons of nucleus of tractus solitarius of vagus which in turn decrease central and peripheral sympathetic activities resulting in decreased BP.
• It also inhibits the decarboxylation of DOPA and 5-HT, thus decreased sympathetic tone.
• It also directly reduces renin activity which is responsible for conversion of angiotensin-I to angiotensin-II thereby reducing BP.
• Pharmacokinetics:– Well absorbed from the GIT– Half-life: 1.5 hrs– Antihypertensive effects; 4-6 hrs– Effective twice daily– Dose: 1-2 g in divided doses
• Indications:– Moderate to severe hypertension– Hypertensive crisis– Pheochromocytoma– Malignant carcinoid
• Adverse effects:– Mental symptoms (sedation, lassitude, vertigo)– Electrolyte imbalance– Thrombocytopenia– Headache– Psychic depression– Lactation– Dryness of mouth– Oedema– Postural hypotension– Allergic reaction
Unique side effects:• Flushing of skin• Failure of ejaculation• Depression• Hemolytic anemia• Granulocytopenia• Hepatic disturbance
Clonidine
• It is centrally acting sympatholytic agent (α2 adrenoceptor agonist) and acts by decreasing central sympathetic activity.
• Mechanism of action: It combines with α2 –receptors of lower brainstem which in turn inhibits release of noradrenaline from the neurons. It decreases sympathetic activity which results in decreased cardiac output due to decrease heart rate and relaxation of capacitance vessels. Thus BP is decreased.
Pharmacological actions of Clonidine:1. CNS: suppress sympathetic outflow2. CVS: decrease heart rate; decrease CO3. Blood vessels: reduction in resistance and relaxation of
capacitance vessels
Indications:4. Hypertension5. Prophylaxis of migraine6. Diagnosis of pheochromocytoma
• Adverse effects:– Sedation– Dry mouth– Drowsiness– Rebound hypertension
• Pharmacokinetics of Clonidine:– Bioavailability: 75%– Half-life : 8-12 hours– Excretion: half of the drug excreted unchanged– Dose: 0.2 and 1.2 mg/day
• Sudden withdrawal effects: It can result in life threatening crisis. Patient exhibit
nervousness, tachycardia, headache and sweating if one or two dose is omitted.
Note: sudden withdrawal of the drug must be avoided. If required should be done gradually.
Calcium channel blockers
• Calcium is the chief ion required for– Cardiac contraction– Smooth muscle contraction– Propagation of cardiac impulse
• Classification of Ca++ channel blockers1. Dihydropyridine family:
– Nifedipine – Nicardipine– Nisoldipine– Amlodipine– isradipine
2. Miscellaneous:– Verapamil– Deltiazem– Bepridil
• General pharmacokinetics for Ca++ channel blockers – Orally administered– Highly protein bound– Hepatic first pass metabolism– Renal excretion
• Mechanism of action: Calcium channel blockers bind with voltage
dependent Ca++ channel (L-type) in depolarised membrane. The resultant effect is relaxation of the smooth muscles and negative ionotropic and chronotropic action in the heart.
• Pharmacological action of Calcium channel blockers1. CVS:
1. Dilates main coronary vessels: improves myocardial perfusion2. Negative chronotropic effect: cardiac slowing and AV block3. Negative ionotropic effect: decrease force of contraction 4. Vasodilation: decrease total peripheral resistance Smooth
muscles• Smooth muscles:
1. Vascular smooth muscle: generalized relaxation2. Coronary vasodilation: antianginal action3. Visceral smooth muscle: relaxation of biliary tract; uterus and
bladder.
• Indications: 1. Angina pectoris (variant)2. Hypertension3. Cardiac arrhythmias4. Prevention of ischemic neurological damage due
to subarachnoid damage5. Raynaud’s disease6. Migraine7. Premature labour
• Contraindication:– Heart failure– Bradycardia– Second or third degree AV block– Sick sinus syndrome– Wolf Parkinson-White syndrome
• Adverse effects:• Due to vasodilation:
– Postural hypotension, reflex tachycardia– Bradycardia, palpitation– Headache, flushing, dizziness, ankle edema
• Gastrointestinal– Constipation– Nausea, vomiting– Gum hypertrophy
ACE-Inhibitors
• Angiotensin converting enzyme (ACE) inhibitors are :– Captopril– Enalapril– Lisinopril– Ramipril
• ACE inhibitors act by inhibiting the conversion of angiotensin I to angiotensin II; which is a powerful vasoconstrictor. It acts preferably on angiotensin sensitive vascular bed of kidney, brain and brain.
Mechanism of Action
• It inhibits the conversion of angiotensin I to angiotensin II, thus vasoconstrcitive action of angiotensin II is inhibited.
• Also ACE causes inactivation of bradykinin (vasodilator peptides) but in presence of ACE inhibitors bradykinin is active and causes vasodilation which in turn decrease TPR and finally BP.
Pharmacological actions
1. Vasodilation (reduction of TPR)2. Reduce preload and afterload 3. Reduction in the secretion of aldosterone so
decreased salt and water retention.4. Increase in renal blood flow.
Indications
• Hypertension• Renovascular hypertension due to excess renin• Malignant hypertension• Hypertensive crisis of scleroderma• End stage renal disease
• Refractory heart failure• Ischemic heart disease
Adverse effects
• First dose hypotension• Dry cough• Angioneurotic oedema• Hyperkalaemia• Loss of appetite• Stomatitis• Abdominal pain• Neutropenia• Proteinuria• Blood disorders
Contraindications
• Systolic blood pressure < mm Hg• Bilateral renal artery stenosis• Second and third trimester of pregnancy• Renal failure
Angiotension receptor blockers
• These are the agents that act on the angiotensin type I (AT1) receptor.
• Drugs:– Losartan– Valsartan– Candesartan– Eprosartan– Irbesartan– Telmisartan
• Unique features of ARBs from ACE-inhibitors:– These agents are unique from ACE –inhibitors in
that they don’t have effect on bradykinin.– They cause more complete inhibition of
angiotensin action because besides ACE other enzymes are present which can angiotensin II.
Losartan:
Mechanism of action: It causes antagonism in the angiotensin receptor thus causing a complete blockade of angiotensin II activity.
Pharmacokinetics:– Orally administered– Extensively metabolized; metabolites retain
activity– Plasma half-life: 2 hrs– Dose: 50 mg/d; can range from 25-100 mg/d
• Indications:– Hypertension
• Adverse effects: similar to ACE-inhibitors except that no angioedema and cough is present; both of which are mediated via bradykinin.
• Contraindications: – pregnancy
• Saralasin is an analog and competitive inhibitor of angiotensin II at its receptors.
• It also blocks the pressor and aldosterone releasing effect of infused angiotensin II and reduce blood pressure in high renin activity state such as renal artery stenosis.
• It has been withdrawn from market due to its unpredictable pharmacological outcomes.
Vasodilators
• Drugs:1. Oral vasodilators:
• Hydralazine • Minoxidil
2. Parenteral vasodilators:• Nitroprusside• Diazoxide• Fenoldopam
• Mechanism of action : This class of compounds cause the dilation of arteries or both arteries and veins; thus reducing overall peripheral resistance and in turn decreases the blood pressure.
• Hydralazine: – It is a hydrazine derivative and is known to dilate arterioles only
but not veins.– It causes tachyphylaxis to hypertensive effects developed rapidly.– It can be used in combination.
• Pharmacokinetics:– Orally administered– Extensive 1st pass metabolism– Low bioavailability– Half-life 2-4hrs– Dose: 40-200mg/day.
• Adverse effects:– Headache– Nausea– Anorexia– Palpitations– Seating – Flushing– Systemic lupus erythrematosus (SLE)
• Minoxidil– Orally active; half life-4hrs; 5-10mg/d in two doses– Vasodilation results due to opening of K+ ions
which brings the membrane to hyperpolarized state, producing relaxation.
– It also dilates arterioles but not veins.– Headache, sweating and hypertrichosis,
tachycardia and angina and edema are side effects
• Fenoldopam: • It is indicated for severe hypertension and
postoperative hypertension.• Acts as Dopamine (D1 receptors) agonist
resulting dilation of peripheral ateries.• Given parenterally (i.v. infusion); extensively
metabolized and very short half-life of 5 mins.• Very small dose of 0.025-0.05µg/kg/min.
Individualised care approach Calcium channel blockers :
Suited for :1) Elderly 2) Isolated systolic
hypertension3) Asthma/COPD patients 4) Raynauds disease/
migraine5) Pregnant hypertensive
Avoid in :1) CHF2) Conduction defects 3) Patients receiving beta
blockers 4) IHD/ post MI5) Left ventricular hypertrophy6) Males with enlarged
prostate 7) GERD
ACE Inhibitors • Suited for :1) High renin cases or those on low
salt 2) Physically active 3) Diabetics/ with nephropathy 4) Co existing angina / post MI
cases5) Coexisting Left ventricular failure
/ left ventricular hypertrophy6) Gout/PVD?Dyslipidemic patients
• Avoided in :1) Bilateral renal artery
stenosis 2) Pregnancy 3) Hyperkalemia 4) Pre existing dry cough
Beta adrenergic blockers • Suited for :1) Angina or post MI cases 2) Coexisting anxiety or
techycardia 3) Non obese high renin
hypertensive 4) Pregnancy
• Avoided in :1) CHF2) Bradycardia , conduction
defects 3) Asthma / PVD 4) Diabetic or borderline
glucose tolerance 5) Abnormal lipid profile 6) Patient to remain physically
active
Diuretics :• Suited for :1) Elderly patients 2) Low renin hypertensive 3) Isolated systolic
hyeprtension 4) Obese with volume
overload 5) Renal disease with salt
retention 6) Low cost therapy
• Avoided in :1) Young active hypertensive 2) Diabetes 3) Gout 4) Abnormal lipid profile 5) Pregnancy induce
hypertension
Combination therapy
1) Drugs increasing renin activity ( diuretics . Vasodilators ,
CCBs, ACE inhibtors ) with drugs having low renin activity ( beta blockers , clonidine , methyl dopa )
2) Drugs causing fluid retention( adrenergic blockers except
beta blockers ) with diuretics3) Drugs causing tachycardia ( hydralazine , DHPs)
with non selective beta blockers 4) ACE inhibitors / AT1 blockers with diuretics 5) CCB with diuretics6) Beta blocker + prazosin
• Combinations to be avoided :1) Adrenergic blocker with clonidine 2) Hydralazine with prazosin3) Verapamil/diltiazem with beta blocker 4) Methyl dopa + clonidine
Hypertension in pregnancy
Suitable drugs 1) Methyl dopa 2) Hydralazine 3) Dihydropyridine CCBs4) Cardioselective adrenergic
blockers ( atenolol, pindolol, acebutolol)
5) Prazosin 6) Clonidine
Drugs to be avoided 1) Diuretics 2) ACE inhibitors 3) Reserpine 4) Non selective beta blockers 5) Sod nitroprusside
ABCD method of drug sequencing
Younger and non black • Step 1 : AOlder and black • Step 1: C or D • Step 2: A+ c or D • Step 3 : A+C+ D • Step 4 : Add alpha blocker or spironolactone
or Beta blocker
Diabetes
• First line therapy :Type 1 : monotherapy :ACE inhibitors / AT1 blockers Combination : + beta blockers / CCBs / thiazides/
alpha blockers Type 2 :ACE inhibitors / AT1 blockers / CCBs
Renal disease
• ACE inhibitors • Thiazide diuretics not used in severe renal
impairment, instead loop diuretics are used
Anti-anginal drugs
• Angina pectoris– It is a clinical syndrome characterized by pre-cardiac
pain or discomfort due to myocardial ischemia, which is precipitated by exercise and relief by rest or sublingual nitro-glycerine.
– It occurs when coronary blood flow is insufficient to meet the metabolic requirement of the heart muscle.
– Myocardial oxygen demand mainly depends on• Preload,• After load and • Heart rate
• atherosclerotic angina, classic angina(angina of effort)
• vasospastic or variant angina(Prinzmetal's angina)
• Unstable angina
Determinants of Myocardial Oxygen Consumption.
• Wall stress• Intraventricular pressure• Ventricular radius (volume)• Wall thickness• Heart rate• Contractility
Regulation of smooth muscle contraction and relaxation
1) Increasing cGMP: dephosphorylation of myosin light chains, nitric oxide
2) Decreasing intracellular Ca2+:3) Stabilizing or preventing depolarization of the
vascular smooth muscle cell membrane: increase the permeability of K+ channels,
4) Increasing cAMP in vascular smooth muscle cells: cAMP increases the rate of inactivation of myosin light chain kinase
• Drugs:Organic nitrites and nitrates:
– Nitrites: sodium nitrite, amy-nitrite, octyl-nitrite– Nitrates: glyceryl trinitrate, isosorbide dinitrate
and isosorbide mononitrateCalcium channel blockers:
– Nifedipine– Verapamil– deltiazem
Beta-adrenoceptor blockers– Atenolol– Propranolol– Oxaprenolol
Xanthines:– Theophylline– Aminophylline
Miscellaneous– Dipyradimol
Drugs or Drug Groups under Investigation for Use in Angina.
• Metabolic modulators:eg, ranolazine• Direct bradycardic agents, eg, ivabradine• Potassium channel activators, eg, nicorandil• Rho-kinase inhibitors, eg, fasudil• Sulfonylureas:eg, glibenclamide• Thiazolidinediones/glitazones• Nitric oxide donors: eg, L-arginine• Capsaicin• Amiloride
Organic nitrates
• Pharmacokinetics of organic nitrates:• Glyceryl trinitrate is a short-acting• Undergoes 1st pass metabolism if given orally• Given sublingually usually 500mg tab/day• Onset of action within 15-30 mins• Duration:20-30mins• Used mainly in acute attack.
• Isosorbide di-and mono-nitrates are long acting
• Orally given• Systemic availability more than GTN• Used in prophylaxis.
Mechanism of action:
Organic nitrates act by relaxing smooth muscles of blood vessels. It occurs in following steps:
1. Denitration of org. nitrates ( org nitrates into inorganic)
2. Inorganic nitrates converted to NO (like EDRF)3. Activation of guanylyl cyclase i.e. raised cGMP4. Reduces intracellular Calcium concentration5. Relaxation of vascular smooth muscles
• Pharmaclogical actions:• CVS:
– Reduces preload (due to venodilation)– Reduces afterload (due to generalized vasodilation)– Dilates coronary arteries and increase blood flow to
ischemic areas• Others:
– Relaxation of bronchial smooth muscle– Relaxation of GIT smooth muscle i.e. decreased motility– Relaxation of smooth muscle of biliary tract, urethra and
uterus.
• Indications:– Angina pectoris– Congestive heart failure– Myocardial infarction
• Adverse effects:– Flushing of face– Throbbing headache– Postural hypotension– Syncope– Nitrate tolerance
• Contraindication:– Organic nitrate intolerence– Angina due to severe anemia– High intra-cranial pressure– Glaucoma– Migraine
• Nitrate tolerance:• During long term use , the nitrate effects is
gradually lowered and finally resulting in partial or complete loss of its benefit.
• Mechanism is reduced production of cGMP in vascular smooth muscles.
• Nitrate free period of 1-2 hours every 24 hrs helps prevent development of tachyphylaxis.
Anti-arrhythmic drugs
• Cardiac arrhythmias: The disorder in rate and rhythm of cardiac
contraction due to myocardial damage is known as cardiac arrhythmias.
• Cardiac arrhythmias consist of cardiac depolarizations that deviate form the normal in one or more aspects;– Abnormality at site of origin of impulse– Its rate and regularity– Its conduction
• Vaughan Williams classificationClass-I: Na+ channel blocker
Group A: Quinidine Procainamide Disopyramide Pharmacological actions:– Membrane stabilizing action– Prolongs refractory period– Prolongs action potential
Group B: Lidocaine Mexiletine Tocainide PhenytoinMembrane stabilizing actionShortens refractory periodShortens action potential
Group C: Flecainide EncanideMembrane stabilizing actionNo effect on action potential
Class-II drugs: β-blockers (counteracts catecholamines)
Propranolol Atenolol Metoprolol SotalolAbolish SA firingDecrease contractilityIncrease AV refractoriness
Class-III drugs: Repolarization prolonging Amidarone BretyliumProlongs refractory periodProlongs action potentialPrevents re-entry rhythm
Class-IV drugs: Calcium channel blockers Verapamil Deltiazem Inhibits slow Calcium channelsDepress contractility of AV node.
Quinidine
• It is a class-I anti-arrhythmic drug. It is an optical isomer of quinine (anti-malarial drug).
Pharmacokinetics:– Orally active; i.v. in emergency; i.m. painful– 80% bound to plasma proteins– Half-life: 4-6 hrs– Metabolized by liver (75%)– Excretion: unchanged fraction by kidney
Pharmacological actions of quinidine:– Cardiac tissue:
• Reduce automaticity• Reduce excitability• Reduce conductivity• Prolong refractory period• Reflex tachycardia
– Other action:• Anti-malarial• Anti-pyretic• Decrease B.P (vasodilation)
• Adverse effects:– Heart block– Sinus arrest– Myocardial depression– Q-T prolongation– Ventricular fibrillation– Nausea – Vomiting– Diarrhoea – Rash – Oedema
• Indications:• As anti-arrhythmic used in,
– Atrial fibrillation and flutter– Ventricular fibrillation and flutter– Paroxysmal supra-ventricular tachycardia– Premature supra-ventricular tachycardia– Atrial, nodal and ventricular premature beats
• Also as anti-malarial• Anti-pyretic• During digitalis therapy
• Cinchonism:– Headache, vertigo– Blurred vision– Tinnitus
• Contraindications:– Quinidine intolerance– Digitalis intoxication– Heart failure– Hypotension– hypokalemia
• Propranolol as anti-arrhythmic drug:– It blocks β-receptors in heart, thereby exerts
• Negative inotropic effect• Negative chronotropic effect• Depress atrioventricular conduction• Depresses automaticity
– It has:• Anti-arrhythmic effect• Anti-hypertensive effect• Anti-anginal-effect in CVS.
Lidgnocaine
• It is a local-anesthetic agent.• Can terminate arrhythmia if quinidine fails• Parenteral administration: i.v./i.m
Indications:– As local anesthetic– As anti-arrhythmic
• Mechanism of anti-arrhythmic effect of lignocaine:– It has membrane stabilizing effect by blocking
both activated and inactivated sodium channels; which in turn supresses SA node and also ectopic beats.
– Shortens refractory period and action potential; make uniform rhythm
• Adverse effects:– Bradycardia– Hypotension– Dizziness– Blurred vision– Sleepiness– Confusion– Convulsion